References
- Brumm MV, Nguyen QD. Fluocinolone acetonide intravitreal sustained release device—a new addition to the armamentarium of uveitic management. Int J Nanomed. 2007;2:55–64
- Lim LL, Smith JR, Rosenbaum JT. Retisert (Bausch & Lomb/Control Delivery Systems). Curr Opin Invest Drugs. 2005;6:1159–1167
- Jaffe GJ, Martin D, Callanan D, et al. Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study. Ophthalmology. 2006;113:1020–1027
- Khalifa Y, Loh AR, Acharya NR. Fluocinolone acetonide intravitreal implants in Vogt-Koyanagi-Harada disease. Ocul Immunol Inflamm. 2009;17:431–433
- Mahajan VB, Gehrs KM, Goldstein DA, et al. Management of sympathetic ophthalmia with the fluocinolone acetonide implant. Ophthalmology. 2009;116:552–557 e551
- Patel CC, Mandava N, Oliver SC, et al. Treatment of intractable posterior uveitis in pediatric patients with the fluocinolone acetonide intravitreal implant (Retisert). Retina. 2012;32:537–542
- Park UC, Kim SJ, Yu HG. Cytomegalovirus endotheliitis after fluocinolone acetonide (Retisert) implant in a patient with Behcet uveitis. Ocul Immunol Inflamm. 2011;19:282–283
- Rofagha S, Prechanond T, Stewart JM. Late spontaneous dissociation of a fluocinolone acetonide implant (Retisert). Ocul Immunol Inflamm. 2013;21:77–78
- Jaffe GJ. Reimplantation of a fluocinolone acetonide sustained drug delivery implant for chronic uveitis. Am J Ophthalmol. 2008;145:667–675
- Allen RC, Suhler EB, Flaxel CJ, et al. Long-term follow-up of patients treated with multiple fluocinolone acetonide implants for noninfectious uveitis. J Ophthalmic Inflamm Infect. 2012;2:177–182
- Jabs DA, Nussenblatt RB, Rosenbaum JT, et al. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol. 2005;140:509–516
- Taban M, Lowder CY, Kaiser PK. Outcome of fluocinolone acetonide implant (Retisert) reimplantation for chronic noninfectious posterior uveitis. Retina. 2008;28:1280–1288
- Yeh S, Cebulla CM, Witherspoon SR, et al. Management of fluocinolone implant dissociation during implant exchange. Arch Ophthalmol. 2009;127:1218–1221
- Wan W, Stewart JM. Use of a high infusion rate to prevent posterior dislocation of fluocinolone acetonide implant during surgical removal. Ocul Immunol Inflamm. 2011;19:214–215
- Nicholson BP, Singh RP, Sears JE, et al. Evaluation of fluocinolone acetonide sustained release implant (Retisert) dissociation during implant removal and exchange surgery. Am J Ophthalmol. 2012;154:969–973 e961
- Jaffe GJ, McCallum RM, Branchaud B, et al. Long-term follow-up results of a pilot trial of a fluocinolone acetonide implant to treat posterior uveitis. Ophthalmology. 2005;112:1192–1198
- Oh EK, Lee EK, Yu HG. Long-term results of fluocinolone acetonide intravitreal implant in Behcet intractable posterior uveitis. Can J Ophthalmol. 2014;49:273–278
- Multicenter Uveitis Steroid Treatment Trial Research G, Kempen JH, Altaweel MM, Holbrook et al. The multicenter uveitis steroid treatment trial: rationale, design, and baseline characteristics. Am J Ophthalmol. 2010;149:550–561 e510
- Jabs DA, Rosenbaum JT, Foster CS, et al. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol. 2000;130:492–513
- Jaffe GJ, Ben-Nun J, Guo H, et al. Fluocinolone acetonide sustained drug delivery device to treat severe uveitis. Ophthalmology. 2000;107:2024–2033